Skip to main content
OpenTrials
Completed

NCT Number: NCT04796142

Medication Reconciliation in Oncologic Patients

To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medication Reconciliation

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alessandro Passardi

Meldola, FC, 47014, Italy

About this study

This trial will explore the alliance between a Cancer Institute and the community pharmacies to improve medication reconciliation in healthcare transitions, and will validate a new integrated IT platform.

Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy participating to the trial, and to perform the pharmacological survey before every cycle of chemotherapy.

This will be sent through the new IT platform to the electronic medical record of IRST, and the Oncologist will perform the reconciliation.

Data about concomitant medications and possible interactions will be exensively analyzed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult ≥18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Patients receiving an anticancer treatment
  • Clear understanding of the Italian language; written informed consent.

Exclusion criteria

  • None

Treatment and study plan

Medication reconciliation

Other

medication reconciliation

Primary outcomes

  1. medication recognition and reconciliation maintenance

    Time frame: At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days)

    number of reconciliations per patient

Sponsors and collaborators

Lead sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Other

Registry information

Official study title

An Integrated Model to Increase Medication Recognition and Reconciliation in Oncologic Patients

Acronym: PROF2

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Mar 12, 2021
Registry last updated
Dec 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.